Anti-CD276 CAR T-cell therapy (Persongen )

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD276 CAR T-cell therapy (Persongen )
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD276 antigen inhibitorsCell replacements
TargetsCD276 antigen
Therapy Area/IndicationsLung NeoplasmsStomach NeoplasmsNeuroblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Zhengzhou University
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Active IndicationsLung NeoplasmsStomach NeoplasmsNeuroblastoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A